Literature DB >> 20633186

Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions.

Annemarie C de Vries1, Jelle Haringsma, Richard A de Vries, Frank Ter Borg, Nicole C T van Grieken, Gerrit A Meijer, Herman van Dekken, Ernst J Kuipers.   

Abstract

BACKGROUND: Endoscopic surveillance of pre-malignant gastric lesions may add to gastric cancer prevention. However, the appropriate biopsy regimen for optimal detection of the most advanced lesions remains to be determined. Therefore, we evaluated the yield of endoscopic surveillance by standardized and targeted biopsy protocols.
MATERIALS AND METHODS: In a prospective, multi-center study, patients with intestinal metaplasia (IM) or dysplasia (DYS) underwent a surveillance gastroscopy. Both targeted biopsies from macroscopic lesions and 12 non-targeted biopsies according to a standardized protocol (antrum, angulus, corpus, cardia) were obtained. Appropriate biopsy locations and the yield of targeted versus non-targeted biopsies were evaluated.
RESULTS: In total, 112 patients with IM (n = 101), or low-grade (n = 5) and high-grade DYS (n = 6) were included. Diagnosis at surveillance endoscopy was atrophic gastritis (AG) in one, IM in 77, low-grade DYS in two, high-grade DYS in three, and gastric cancer in one patient. The angulus (40%), antrum (35%) and lesser curvature of the corpus (33%) showed the highest prevalence of pre-malignant conditions. Non-targeted biopsies from the lesser curvature had a significantly higher yield as compared to the greater curvature of the corpus in diagnosing AG and IM (p = .05 and p = .03). Patients with extensive intragastric IM, which was also present at the cardia were at high risk of a concurrent diagnosis of dysplasia or gastric cancer. High-grade DYS was detected in targeted biopsies only.
CONCLUSIONS: At surveillance endoscopies, both targeted and non-targeted biopsies are required for an appropriate diagnosis of (pre-)malignant gastric lesions. Non-targeted biopsies should be obtained in particular from the antrum, angulus and lesser curvature of the corpus.

Entities:  

Mesh:

Year:  2010        PMID: 20633186     DOI: 10.1111/j.1523-5378.2010.00760.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  22 in total

1.  Clinical guidelines: Consensus for the management of patients with gastric polyps.

Authors:  Paul J Kelly; Gregory Y Lauwers
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-30       Impact factor: 46.802

Review 2.  Performance measures for upper gastrointestinal endoscopy: A European Society of Gastrointestinal Endoscopy quality improvement initiative.

Authors:  Raf Bisschops; Miguel Areia; Emmanuel Coron; Daniela Dobru; Bernd Kaskas; Roman Kuvaev; Oliver Pech; Krish Ragunath; Bas Weusten; Pietro Familiari; Dirk Domagk; Roland Valori; Michal F Kaminski; Cristiano Spada; Michael Bretthauer; Cathy Bennett; Carlo Senore; Mário Dinis-Ribeiro; Matthew D Rutter
Journal:  United European Gastroenterol J       Date:  2016-08-21       Impact factor: 4.623

3.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

4.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

5.  Follow-up of intestinal metaplasia in the stomach: When, how and why.

Authors:  Angelo Zullo; Cesare Hassan; Adriana Romiti; Michela Giusto; Carmine Guerriero; Roberto Lorenzetti; Salvatore Ma Campo; Silverio Tomao
Journal:  World J Gastrointest Oncol       Date:  2012-03-15

6.  Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.

Authors:  Jennifer M Yeh; Chin Hur; Zachary Ward; Deborah Schrag; Sue J Goldie
Journal:  Gut       Date:  2015-03-16       Impact factor: 23.059

Review 7.  Screening for and surveillance of gastric cancer.

Authors:  Debora Compare; Alba Rocco; Gerardo Nardone
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

8.  Intestinal metaplasia surveillance: searching for the road-map.

Authors:  Angelo Zullo; Cesare Hassan; Alessandro Repici; Bruno Annibale
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

9.  Gastric intestinal metaplasia and early gastric cancer in the west: a changing paradigm.

Authors:  Justin M Gomez; Andrew Y Wang
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-06

10.  Overview of Current Concepts in Gastric Intestinal Metaplasia and Gastric Cancer.

Authors:  David S Jencks; Jason D Adam; Marie L Borum; Joyce M Koh; Sindu Stephen; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.